USPTO serial 79069161
Serial No. 79069161
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 6, 2010
- Examiner
- MARTIN, JENNIFER MCGARRY
- Law office
- MADRID PROCESSING UNIT
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with Serial No. 79069161?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Shijiazhuang Yiling; Pharmaceutical Co., Ltd.
Hebei Province, CN
Other trademarks owned by Shijiazhuang Yiling; Pharmaceutical Co., Ltd.
Shijiazhuang Yiling; Pharmaceutical Co., Ltd.
Hebei Province, CN
Other trademarks owned by Shijiazhuang Yiling; Pharmaceutical Co., Ltd.
SHIJIAZHUANG YILING PHARMACEUTICAL INC.
CN
Other trademarks owned by SHIJIAZHUANG YILING PHARMACEUTICAL INC.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
William J. Seiter
WILLIAM J. SEITER Seiter Legal Studio2500 Broadway, Bldg F, Suite F-125Santa Monica, CA 90404UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of cardiovascular system diseases, namely, hypertension, and heart failure; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of nutrition metabolism barrier diseases, namely, malnutrition and beriberi; Pharmaceutical preparations for the treatment of metabolism diseases, namely, diabetes, obesity, diabetic ketoacidosis, hypoxemia DKA and high fat proteinemia; Pharmaceutical preparations for the treatment of endocrine system diseases, namely, next cerebral ganglion pituitary gland sickness, thyroid gland sickness, ophoropathy and parathyroid sickness; Pharmaceutical preparations for the treatment of circulatory system diseases, namely, shock, heart valve sickness, arrhythmia, arteriosclerosis, cardiomyopathy periphery blood vessel disease, hypertensive disease and pericarditis; Pharmaceutical preparations for the treatment of respiratory disorder, namely, chronic bronchitis, bronchial asthma, disease of pulmonary circulation, pneumonia and acute trachea bronchitis; Pharmaceutical preparations for the treatment of digesting system diseases, namely, abdominal pain, constipation, diarrhea, cholecystitus, liver cirrhosis, liver function failure and gastritis; Pharmaceutical preparations for the treatment of urinary system diseases, namely, kidney stone, renal tumor, chronic kidney function failure, urinary tract infection and cystonephrosis; Pharmaceutical preparations for the treatment of hematopoietic system diseases, namely, anemia, leukemia and lymphoma; Pharmaceutical preparations for the treatment of immune system diseases, namely, serum sickness, allergic shock and allergic rhinitis; Pharmaceutical preparations for the treatment of rheumatic diseases and osteoarthritis, namely, rheumatic fever, lupus erythematosus, sjogren's syndrome, behcet disease and dermatomyositis; Pharmaceutical preparations for the treatment of nerve diseases, namely, schizophrenia and neurosis; Pharmaceutical preparations for the treatment of nervous system diseases, namely, headache, multiple sclerosis and muscle diseases; Pharmaceutical preparations for the treatment of skin diseases, namely, eczema, belt-shaped blister measles, namely, herpes zoster, connective tissue disease, lupus erythematosus and nervous dermatitis; Pharmaceutical preparations for the treatment of reproductive system inflammation, namely, pelvic inflammatory disease, cervicitis and vestibule big gland inflammation; Pharmaceutical preparations for the treatment of natural dissemination diseases, namely, gonorrhea, syphilis and AIDS; Pharmaceutical preparations for the treatment of female reproductive system tumor, namely, sarcoma uteri, carcinoma of cervix and endometrium cancer; Pharmaceutical preparations for the treatment of menopathy, namely, menopause, painful menstruation and menopause syndrome; Pharmaceutical preparations for the treatment of newborn symptom and diseases, namely, the newborn faints from fright, newborn vomit and newborn septicaemia; Pharmaceutical preparations for the treatment of surgical department conditions, namely, tetanus, wounds and tumors | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Shijiazhuang Yiling; Pharmaceutical Co., Ltd.
- Other trademarks owned by Shijiazhuang Yiling; Pharmaceutical Co., Ltd.
- Other trademarks owned by SHIJIAZHUANG YILING PHARMACEUTICAL INC.
- Other trademarks in Class 005
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 31, 2018 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Aug 31, 2018 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Jan 11, 2018 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Aug 4, 2017 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Jul 13, 2017 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Jul 13, 2017 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Jul 11, 2017 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Nov 11, 2016 | C71T | CANCELLED SECTION 71 | — |
| Mar 25, 2016 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 7, 2013 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 28, 2010 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 28, 2010 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 7, 2010 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 6, 2010 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 19, 2010 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 19, 2010 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 14, 2009 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Dec 8, 2009 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 8, 2009 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 8, 2009 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 8, 2009 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 8, 2009 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 20, 2009 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Nov 18, 2009 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 18, 2009 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 18, 2009 | ALIE | ASSIGNED TO LIE | — |
| Nov 5, 2009 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 5, 2009 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 5, 2009 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 24, 2009 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 30, 2009 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 30, 2009 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 30, 2009 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 30, 2009 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 29, 2009 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 26, 2009 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 26, 2009 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 25, 2009 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |